Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with toll-like receptor stimulation to induce immunity to self-antigens in cancer patients

Clinical Cancer Research

Volumn 17, Issue 14, 2011, Pages 4844-4853

  Morse, Michael A ^a   Chapman, Robert ^b   Powderly, John ^c   Blackwell, Kimberly ^a   Keler, Tibor ^d   Green, Jennifer ^d   Riggs, Renee ^d   He, Li Zhen ^d   Ramakrishna, Venky ^d   Vitale, Laura ^d   Zhao, Biwei ^e   Butler, Stephen A ^a   Hobeika, Amy ^a   Osada, Takuya ^a   Davis, Thomas ^d   Clay, Timothy ^a   Lyerly, H Kim ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c Carolina BioOncology Institute   (United States)

^d Celldex Therapeutics Inc   (United Kingdom)

^e MIDDLESEX UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CDX 1307; CHORIONIC GONADOTROPIN BETA SUBUNIT MANNOSE RECEPTOR MONOCLONAL ANTIBODY CONJUGATE; POLYINOSINIC POLYCYTIDYLIC ACID; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RESIQUIMOD; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ANTIGEN PRESENTING CELL; ARTICLE; BALANCE DISORDER; BLADDER CANCER; BONE PAIN; BREAST CANCER; CANCER IMMUNIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CELLULAR IMMUNITY; CHILL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; HYPONATREMIA; IN VITRO STUDY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MYALGIA; OVARY CANCER; PAIN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TESTIS CANCER; TUMOR IMMUNITY; URETER CANCER; WEAKNESS;

ANTIGEN-PRESENTING CELLS; AUTOANTIGENS; CANCER VACCINES; CELL LINE, TUMOR; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MALE; NEOPLASM STAGING; NEOPLASMS; RECOMBINANT FUSION PROTEINS; SKIN; TOLL-LIKE RECEPTORS; TREATMENT OUTCOME;

EID: 79959545223     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0891     Document Type: Article

References (33)

1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
2. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995;182:389-400.
3. Ramakrishna V, Treml JF, Vitale L, Connolly JE, O'Neill T, Smith PA, et al. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J Immunol 2004;172:2845-52. (Pubitemid 38263669)
4. Engering A, Geijtenbeek TB, van Vliet SJ, Wijers M, van Liempt E, Demaurex N, et al. The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J Immunol 2002;168:2118-26. (Pubitemid 34171810)
5. Martinez-Pomares L, Hanitsch LG, Stillion R, Keshav S, Gordon S. Expression of mannose receptor and ligands for its cysteine-rich domain in venous sinuses of human spleen. Lab Invest 2005;85:1238-49. (Pubitemid 41348639)
6. He LZ, Crocker A, Lee J, Mendoza-Ramirez J, Wang XT, Vitale LA, et al. Antigenic targeting of the human mannose receptor induces tumor immunity. J Immunol 2007;178:6259-67. (Pubitemid 46717409)
7. Triozzi PL, Stevens VC. Human chorionic gonadotropin as a target for cancer vaccines. Oncol Rep 1999;6:7-17.
8. Alfthan H, Haglund C, Roberts P, Stenman UH. Elevation of free beta subunit of human choriogonadotropin and core beta fragment of human choriogonadotropin in the serum and urine of patients with malignant pancreatic and biliary disease. Cancer Res 1992;52:4628-33.
9. Moutzouris G, Yannopoulos D, Barbatis C, Zaharof A, Theodorou C. Is beta-human chorionic gonadotrophin production by transitional cell carcinoma of the bladder a marker of aggressive disease and resistance to radiotherapy? Br J Urol 1993;72:907-9.
10. Iles RK, Persad R, Trivedi M, Sharma KB, Dickinson A, Smith P, et al. Urinary concentration of human chorionic gonadotrophin and its fragments as a prognostic marker in bladder cancer. Br J Urol 1996;77:61-9.
11. Syrigos KN, Fyssas I, Konstandoulakis MM, Harrington KJ, Papadopoulos S, Milingos N, et al. Beta human chorionic gonadotropin concentrations in serum of patients with pancreatic adenocarcinoma. Gut 1998;42:88-91. (Pubitemid 28228393)
12. Lundin M, Nordling S, Lundin J, Alfthan H, Stenman UH, Haglund C. Tissue expression of human chorionic gonadotropin beta predicts outcome in colorectal cancer: a comparison with serum expression. Int J Cancer 2001;95:18-22.
13. Hotakainen K, Ljungberg B, Paju A, Rasmuson T, Alfthan H, Stenman UH. The free beta-subunit of human chorionic gonadotropin as a prognostic factor in renal cell carcinoma. Br J Cancer 2002;86:185-9. (Pubitemid 34185143)
14. Iles RK. Ectopic hCGbeta expression by epithelial cancer: malignant behaviour, metastasis and inhibition of tumor cell apoptosis. Mol Cell Endocrinol 2007;260-262:264-70. (Pubitemid 44792339)
15. Butler SA, Ikram MS, Mathieu S, Iles RK. The increase in bladder carcinoma cell population induced by the free beta subunit of human chorionic gonadotrophin is a result of an anti-apoptosis effect and not cell proliferation. Br J Cancer 2000;82:1553-6. (Pubitemid 30204361)
16. + T lymphocytes. Cancer Immunol Immunother 2002;50:673-81.
17. Talwar GP, Singh OM, Gupta SK, Hasnain SE, Pal R, Majumbar SS, et al. The HSD-hCG vaccine prevents pregnancy in women: feasibility study of a reversible safe contraceptive vaccine. Am J Reprod Immunol 1997;37:153-60. (Pubitemid 27101742)
18. Moulton HM, Yoshihara PH, Mason DH, Iversen PL, Triozzi PL. Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival. Clin Cancer Res 2002;8:2044-51. (Pubitemid 34753572)
19. He LZ, Ramakrishna V, Connolly JE, Wang XT, Smith PA, Jones CL, et al. A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin beta. Clin Cancer Res 2004;10:1920-7. (Pubitemid 38375548)
20. Narayan P, Gray J, Puett D. Yoked complexes of human choriogonadotropin and the lutropin receptor: evidence that monomeric individual subunits are inactive. Mol Endocrinol 2002;16:2733-45. (Pubitemid 36024178)
21. Borrello I, Pardoll D. GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev 2002;13:185-93. (Pubitemid 34229392)
22. Villinger F. Cytokines as clinical adjuvants: how far are we?Expert Rev Vaccines 2003;2:317-26.
23. Chang DZ, Lomazow W, Joy Somberg C, Stan R, Perales MA. Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines. Hematology 2004;9:207-15. (Pubitemid 38997060)
24. Zanoni I, Granucci F. Regulation of antigen uptake, migration, and life-span of dendritic cell by Toll-like receptors. J Mol Med 2010;88:873-80.
25. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005;6:769-76. (Pubitemid 43090462)
26. Makela SM, Osterlund P, Julkunen I. TLR ligands induce synergistic interferon-beta and interferon-lambda1 gene expression in human monocyte-derived dendritic cells. Mol Immunol 2011;48:505-15.
27. Makela SM, Strengell M, Pietila TE, Osterlund P, Julkunen I. Multiple signaling pathways contribute to synergistic TLR ligand-dependent cytokine gene expression in human monocyte-derived macrophages and dendritic cells. J Leukoc Biol 2009;85:664-72.
28. Ramakrishna V, Vasilakos JP, Tario JD Jr, Berger MA, Wallace PK, Keler T. Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells. J Transl Med 2007;5:5.
29. Butler SA, Staite EM, Iles RK. Reduction of bladder cancer cell growth in response to hCGbeta CTP37 vaccinated mouse serum. Oncol Res 2003;14:93-100. (Pubitemid 38166338)
30. Cristina Gauzzi M, Del Corno M, Gessani S. Dissecting TLR3 signalling in dendritic cells. Immunobiology 2010;215:713-23.
31. Gitlin L, Barchet W, Gilfillan S, Cella M, Beutler B, Flavell RA, et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic: polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci U S A 2006;103:8459-64. (Pubitemid 43838477)
32. Schon MP, Schon M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 2008;27:190-9.
33. Butchar JP, Mehta P, Justiniano SE, Guenterberg KD, Kondadasula SV, Mo X, et al. Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy. Clin Cancer Res 2010;16:2065-75.